Gilead beats Covid drug sales fore­casts, takes $1.75B hit on Trodelvy study fail

Gilead said its Covid-19 an­tivi­ral Vek­lury had $692 mil­lion in third-quar­ter sales, far more than the $270 mil­lion Wall Street an­a­lysts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.